The role of advanced glycation end products in the hyperinflammatory response of diabetic wounds
Keywords:
Advanced Glycation End Products, Hyper-Inflammatory Response, Diabetic Wounds
Abstract
Chronic wounds are a frequent complication in diabetic patients and contribute significantly to morbidity and mortality. In the hyperglycaemic state, advanced glycation end products (AGEs) form, affecting collagen cross-linking, cytokine, nitric oxide and growth factor production and molecular signalling pathways. AGE receptors are upregulated and as it activates NF-kappaB, a host of inflammatory cytokines are expressed, exacerbating the self-sustaining inflammatory response seen in diabetic wounds. Therapeutic strategies include inhibiting the formation of AGEs, either directly or by inhibiting the formation of intermediates, and blocking the AGE receptor. A more complete understanding of the biology of the diabetic wound healing process is imperative in the development of successful treatment of diabetic wounds.
Published
2011-06-13
Issue
Section
General Review
By submitting manuscripts to WHSA, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in WHSA for educational and research purposes without obtaining permission.